Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Biotechnology company Allergy Therapeutics said it expected flat sales growth for the next fiscal year on lower patient clinic visits owing to Covid-19 restrictions.
The reduced number of patient clinic visits made in spring and early summer 2020 resulting from COVID-19 restrictions was expected to lead to a decrease in new patients in the autumn, the company said.
The company also reported a jump in profit on higher revenue.
For the year ended 30 June 2020, pre-tax profit rose to £8m from £4m as revenue increased by 6% to £78.2m.
The growth for the year was tempered by the impact of the COVID-19 crisis, with sales in March to May 2020 affected by clinics and hospitals being closed to all non-urgent cases, the company said.
'R&D expenses are anticipated to be approximately 70% higher than in 2020 (excluding the one-off legal settlement of £3.2m) as research continues with Grass MATA MPL and our peanut allergy candidate vaccine,' the company said.